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Summary 
Naive T cells require interleukin 4 (IL-4) to develop into IL-4-producing T cells and IL-4 blocks 
development  of such  cells into  interferon 3'  (IFN-3,)  producers.  Prior  studies  in  accessory 
cell-independent priming systems using antireceptor  antibodies as agonists have demonstrated 
that IL-2 is also necessary  for the development of IL-4-producing cells  under these culture conditions. 
Here we have examined the role of IL-2 and the CD28 costimulation pathway in priming for 
IL-4 and IFN-3' production using a more physiologic model. This involved antigen presentation 
by accessory cells to naive CD4 + T  cells from transgenic  mice whose cells express a T  cell 
receptor (TCR)  specific for a cytochrome c peptide  in  association with I-E  k.  With  splenic 
antigen-presenting cells (APCs), inhibition of CD28 costimulation by the fusion protein CTLA4- 
immunoglobulin (Ig) blocked effective priming. Similarly, transfected fibroblasts expressing both 
MHC class II and the CD28 ligand B7 could prime for IL-4 production and such priming also 
was blocked by CTLA4-Ig. However, APCs deficient in CD28 ligands also could prime TCR 
transgenic T  cells to become IL-4 producers if an exogenous  source of IL-2,  as well as IL-4, 
was provided,  and the inhibition of priming seen with splenic or transfected fibroblast APCs 
in the presence of CTLA4-Ig could be reversed by addition of IL-2. Likewise, priming for IFN-3' 
production could be blocked by CTLA4-Ig and reversed by IL-2. Thus, we conclude that IL-2 
plays a critical  role  in  priming naive CD4 §  T  cells to  become IL-4  or IFN-3" producers. 
Engagement of the CD28 pathway, although normally important in such priming, is unnecessary 
in the presence of exogenous IL-2. 
L 
mphokine production by T cells plays an essential role 
in immune responses. After a short course of activation, 
naive T cells that produce only IL-2 can develop  into "effector" 
ceils capable of producing the key immunoregulatory cytokines 
IL-4 or IFN-3' (1, 2). The pattern of lymphokines produced 
by such effector cells plays a central role in determining the 
qualitative nature of the immune response to an infectious 
agent or vaccine, and thus,  the control of this maturation 
of effector function has been of great interest. We and others 
(3-10) have demonstrated that lymphokines themselves can 
regulate this process. Initial studies, using an accessory  cell-in- 
dependent system, demonstrated that naive T  cells stimu- 
lated by immobilized anti-CD3 Abs required both IL-2 and 
IL-4 for differentiation into IL-4-producing cells (3). Subse- 
quent studies using naive T cells from mice transgenic for 
genes specifying TCR cr and/3 chains confirmed the require- 
ment for IL-4 for the differentiation of IL-4-producing cells 
(6,  7), but these studies did not address the role of IL-2. 
Receptor-counter receptor costimulatory interactions also 
play an important role in controlling lymphokine produc- 
tion. In particular, the CD28 costimulatory pathway has been 
shown to regulate secretion of several  lymphokines, especially 
IL-2 and to a lesser extent IFN-3', by T ceils that have been 
stimulated  through their TCK (11-16). However, the role 
of the CD28 costimulatory pathway in accessory cell-depen- 
dent priming for IL-4 or IFN-3" production has not been ad- 
dressed. Because of our evidence for an IL-2 requirement in 
priming for IL-4 in the anti-CD3 model, we wished to de- 
termine if CD28 engagement was important for such  priming, 
and, if it was, whether its role was primarily to enhance IL-2 
production, or to provide other essential signals necessary 
for the differentiation process. We report here that antigen 
and accessory cell-dependent priming for IL-4 and IFN-3' 
production in vitro is critically dependent on the activity of 
the CD28 costimulatory pathway, as assessed using inhibi- 
tion by the fusion protein CTLA4-Ig (17). However, the role 
of this pathway seems limited to augmentation of the produc- 
tion of IL-2, and possibly other cytokines. If exogenous IL-2 
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engagement appear unnecessary for priming to occur. These 
data  help  define the  contributions  of both  cell-associated 
costimulatory signals and secreted cytokines to regulation of 
T  cell effector differentiation, with implications for under- 
standing both the normal physiology of lymphokine-guided 
immune responses and the possible effects of exogenous IL-2 
administration in the clinical setting. 
Materials  and Methods 
Animals.  Mice transgenic for TCR c~ and/3 chains yielding 
a receptor specific  for cytochrome c and the MHC class II molecule 
Ec~kE~  k were obtained  from Barbara Fazekas de St.  Groth and 
Mark Davis (Stanford University, Stanford, CA) and maintained 
by crossing to B10.A mice in our animal facilities (7). All mice 
used were homozygous  for I-E  k and expressed the TCR trans- 
genes. Splenic APCs were prepared from virus-free 8-12-wk-old 
B10.A female mice obtained from the Division of Cancer Treat- 
ment, National  Cancer Institute (Frederick, MD). 
Tissue Culture Medium.  DMEM supplemented with 10% heat- 
inactivated FCS, penicillin (100 U/ml), streptomycin (100/~g/ml), 
L-glutamine (2 raM), and 2 ME (50 #M) was used for all stimula- 
tion assays. 
Peptide.  A peptide with the sequence  corresponding to residues 
88-104 of pigeon cytochrome C was synthesized and purified by 
the National Institute of Allergy and Infectious Diseases (NIAID) 
Biological Resources Branch (Bethesda, MD), as previously de- 
scribed (7). 
Recombinant Lymphokines.  Human rib2 was a gift of the Cetus 
Corp. (Emeryville,  CA). Ib2 activity was defined  in terms of"Cetus 
Units". One Cetus unit is equivalent to 0.3 ng. Mouse rib4 was 
obtained by a baculovirus expression system, utilizing a vector into 
which the IL-4 gene had been inserted by C. Watson (Laboratory 
of Immunology, NIAID). One unit of IL4 is equivalent to 0.5 pg. 
Antibodies.  Purified  monodonal rat anti-mouse IL-4 (11Bll) (18) 
was prepared by Verax Corp.  (Lebanon, NH). Anti-Ib2 ($4.B6) 
(19) was  purchased  from Pharmingen  (San Diego,  CA).  The 
CTLA4-Ig fusion protein  contains  the extracellular domain  of 
human CTLA-4 joined to the human  IgCyl segment (17). The 
chimeric monoclonal antibody L6 was the gift of Drs. I. Hellstrom 
and K. E. Hellstrom (Bristol-Meyers Squibb, Seattle, WA). Anti- 
CD28  antibody  was a gift of Dr. James Allison (University of 
California, Berkeley, CA) (20). 
Preparation of T  Cells.  Purified CD4 + LN T  cells were pre- 
pared as previously described (7). Briefly, LN cells were first passed 
through a nylon wool column and then depleted of residual I-E  k§ 
and CD8 § cells by negative selection using magnetic beads. The 
purity and transgene expression of the CD4 + T cells were verified 
by flow cytometric analysis using two-color immunofluorescence 
with PE-labeled anti-CD4  and FITC anti-Vc~11(RR8-1) Abs ob- 
tained from Pharmingen.  In most experiments, >90% of the T 
cells expressed CD4 and Vcdl. 
Preparation of  Accessory Cells.  L cells expressing Ec~E~  k (DCEK 
cells) were prepared as previously described (21, and Miller, J., and 
R. N. Germain, unpublished results). COS-7 cells stably expressing 
Ec~E/3  k were prepared by Dr. Jerry Tanner, Federal Drug Adminis- 
tration (Bethesda, MD), using Ecr  and E~ cDNAs inserted into 
pCMVIE-AK1 vector (22) and transfected into COS.7 cells, fol- 
lowed by selection in G418 and cloning of high expressing cells. 
T-depleted  spleen cells were prepared from B10.A mice by removing 
T cells from splenocytes by treatment  with a cocktail containing 
anti-Thyl.2 (HO134; ATCC TIB 99, American Type Culture Col- 
lection, Rockville, MD) (23), anti-CD4  (GK1.5) (24), and anti- 
CD8  (3.155) (25) Abs  plus  Low-tox  M  rabbit  complement 
(Cedarlane, Westbury, NY). 
Primary and Secondary Stimulation of Transgenic T Cells.  Primary 
stimulation of transgenic T cells was carried out by adding 3  x 
105-1  x  106 CD4 § T cells to individual wells of 24-well plates 
in a total volume of 1 ml together with accessory cells, peptide, 
and lymphokines as described in Results. After 36-48 h, cells were 
transferred for an additional 48 h to 5-ml dishes supplemented with 
fresh medium to allow further expansion. Cultures were washed 
three times and 5  x  104-1 x  105 T cells were restimulated with 
peptide and APC in a total volume of 200/zl in wells of 96-well 
plates for 36 h. Supernatants were collected and assayed for lym- 
phokine. 
Measurement of Lymphokine Production.  An IL-4-dependent line 
(CT.4S) (26), and an IL-2-dependent cell line (CTLL) (27), were 
used to measure IL4 and IL2 production, respectively,  using serial 
dilutions of supernatants and comparing responses to those elicited 
by known amounts of murine rlL-4 and human rlL-2 as standards. 
IFN-3, was assayed by a specific two-site ELISA (28, 29), using 
reference  standard curves prepared using known amounts of  rlFN% 
Results 
COS/I-E  ~ Fail to Stimulate  T  Cell Proliferation in the Ab- 
sence of  Exogenous IL-2 or Anti-CD28.  To assess the respec- 
tive roles of direct CD28 intracellular signaling vs. CD28- 
mediated augmentation of IL-2 availability on T cell priming 
for IL-4 production in an antigen and MHC class II-depen- 
dent  system,  we  utilized COS/I-E  k cells  as  APCs.  COS/ 
I-E  k express little to no CTLA4-reactive protein as assessed 
by FACS  |  (Becton Dickinson & Co., Mountain View,  CA) 
analysis with human CTLA4-Ig chimeric protein (data not 
shown), and thus should fail to activate the CD28 costimu- 
lation pathway.  CD4 § transgenic T cells stimulated with ei- 
ther cytochrome c peptide,  IL-2, or anti-CD28  in the ab- 
sence of COS-I-E  k showed minimal uptake of [3H]thymidine 
(Fig.  1).  When CD4 §  transgenic T  cells were stimulated 
with  COS/I-E  k  and  peptide  alone,  little  stimulation  of 
[3H]thymidine uptake occurred above that seen with COS/ 
I-E  k and peptide without T  cells (Fig.  1).  However, when 
IL-2 was added to these cultures, there was a substantial in- 
crease in DNA  synthesis. The addition of anti-CD28  also 
caused an increase in DNA synthesis. The CD28-mediated 
increase was  completely inhibited by anti-IL-2.  Moreover, 
adding CTLA4-Ig did not diminish DNA synthesis in re- 
sponse to IL-2. Thus,  COS/I-E  k cells  are effective at pep- 
tide presentation to transgenic CD4 § T ceils, but do not in- 
duce IL-2 production without independent provision of T 
cell costimulatory signals. 
IL-2 or Anti-CD28 Is Required for Priming for IL-4 Produc- 
tion in the Absence of a Source of CD28 Ligand.  COS/I-E  k 
cells were then used as APCs to study the roles of IL-2 and 
CD28 stimulation in priming naive TCR transgenic CD4 § 
T  cells to develop into IL-4 producers. Fig.  2 demonstrates 
that, in the presence of COS/I-E  k and peptide, addition of 
IL-4 alone did not result in priming TCR transgenic T cells 
to produce IL-4 upon restimulation. However, adding either 
IL-2 or anti-CD28 induced the cells to produce substantial 
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Figure  1.  COS/I-E  k cells, in the pres- 
ence of peptide, do not stimulate T cells 
to proliferate in the absence of exogenous 
IL-2 or anti-CD28.  CD4 + transgenic T 
cells  (5  x  104) were  stimulated  with 
COS/I-E  k (2  x  104) and peptide (I/zM), 
in the presence of varying combinations of 
anti-CD28 (1/250 dilution), anti-IL-2 (10 
/~g/ml),  and  CTLA4-Ig (10  /zg/ml)  in 
triplicate microcultures (200/A/well). After 
3 d,  cultures were pulsed for 8 h with 
[3H]thymidine and harvested for counting. 
As controls, T cells were incubated with 
either  peptide,  IL-2 or  anti-CD28,  or 
COS/I-E  k were incubated with peptide in 
the absence of T cells. 
amounts of IL-4 when restimulated. The addition of CTLA4- 
Ig to  the  priming  culture  when  both  IL-2 and  IL-4 were 
present did not significantly diminish the subsequent produc- 
tion of IL-4, indicating  that blocking potential stimulation 
of the CD28 pathway does not affect priming for IL-4 produc- 
tion,  provided  exogenous  IL-2 is present. 
Anti-IL-2 Inhibits Priming for IL-4 in the Presence of APCs 
that Express  CD28 Ligands.  To examine  the  role  of more 
physiologic engagement of the CD28/CTLA-4  pathway in 
the priming process, we used as APCs either T-depleted spleen 
or transfected L cells that express I-E  k together with B7 and 
possibly other CD28  ligands  (DCEK cells).  Fig.  3  demon- 
strates that IL-4 is produced only from cells exposed to both 
IL-4 and IL-2 in the priming culture.  If either IL-2 or IL-4 
is neutralized by the addition of mAbs, no IL-4 is produced 
upon  restimulation. 
IL-2 may act as a positive differentiative stimulus or it might 
function  simply to sustain cell viability.  However, priming 
cultures  containing  IL-4 and  anti-IL-2  have a  cell yield of 
30-40%  of cultures carried in IL-2 plus IL-4. Nonetheless, 
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Figure  2.  IL-2  or anti-CD28 is required for priming for IL-4 produc- 
tion in the absence of a source of CD28 ligand(s). CD4 + transgenic T 
cells (1.2 x  106) were stimulated for 4 d with COS/I-E  k (4  x  105), pep- 
tide (1 gM), IL-4 (1,000 U/ml)  -+ anti-CD28 (1/250 dilution), or IL-2 
(10 U/ml)  +  IL-4 (1,000 U/ml)  +- CTLA4-1g (10/~g/ml).  Cells were 
washed and recultured at 5  x  104/200 gl with COS/I-E  k (2.5  x  104) 
and peptide (1 ~m) for 36 h. Supernatants were harvested and IL-4  content 
measured. Results are reported as U/ml of IL-4. 
restimulation  of the  same number  of viable T  cells results 
in  IL-4 production  only from cells primed in the presence 
of IL-2. Thus,  it appears that priming for IL-4 production 
requires the activity of IL-2 in a system in which the APCs 
possess the ability to activate the CD28 dependent costimula- 
tory pathway. 
IL-2 Production Is Inhibited  by CTLA4-Ig  in a Primary Re- 
sponse.  The  data  generated  using  COS/I-E  k  as  well  as 
normal or costimulator-positive  transfectants  all were con- 
sistent with the necessary role of CD28-dependent costimu- 
lation  in  IL-4  priming  being  solely  through  augmented 
production of IL-2. We therefore used CTLA-4-Ig to inhibit 
the  activation  of the  CD28  pathway,  to  further  evaluate 
whether  signaling via this pathway was simply required  to 
generate IL-2 or was providing an additional signal indepen- 
dent of IL-2 that was required for cells to differentiate into 
IL-4 or IFN-y-producing cells. Table 1 illustrates  the effect 
of CTLA4-Ig on production  of IL-2 or IL-4 after primary 
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Figure  3.  Anti-IL-2  inhibits priming for IL-4  in the presence  of costimula- 
tory APCs. CD4 + transgenic T cells (10  s) were stimulated for 4 d with 
T-depleted spleen (5  x  10 s) or DCEK (5  x  l0  s) and peptide (1 gM) in 
the presence of nothing,  IL-4 (1,000 U/ml) plus IL-2 (10 U/ml) or anti- 
IL-2 (10/zg/ml),  or anti-IL-4 (1tBll)  plus IL-2. Cells were washed and 
recultured at 10s/200/zl with T-depleted spleen (10  s) and peptide (1 gm) 
for 36 h. Supernatants were harvested and IL-4 content was measured as 
described in Fig. 2. 
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Primary Response 
T + APC + 88 -  104 +  IL-2 (U/ml)  IL-4 (U/ml) 
0  19  0 
CTLA4-Ig  0.6  0 
L6  20  0 
CD4 + transgenic  T cells (105) were stimulated  for 36 h with T-depleted 
spleen cells (10~), and peptide (1 ~m) in the presence of no additions, 
CTLA4-1g (10 ~g/ml), or L6 (10 gg/ml).  Supernatants  were assessed 
for IL-2 and IL-4 content  by utilizing indicator  cell  lines sensitive  to IL-2 
and IL-4, respectively.  Results are reported as U/ml of IL-2 or IL-4. 
stimulation of CD4 + T  cells  with T-depleted spleen cells 
and peptide 88-104.  In this experiment, CD4 § T  cells were 
stimulated for only 36 h  with APCs and peptide and lym- 
phokine production was assessed. In the absence of CTLA4- 
Ig, 19 U/m1 of IL-2 was made. When CTLA4-Ig was added, 
this was decreased 30-fold to 0.6 U/ml. L6, a control human 
Ig fusion protein, caused no inhibition of IL-2 production. 
To test the effect of inhibiting the CD28 pathway on the 
generation of IL-4-producing cells, CD4 + T  cells were cul- 
tured for 4 d with T-depleted spleen cells, peptide, and IL-4 
in the presence of anti-IL-2, CTLA4-Ig, or IL-2 plus CTLA4- 
Ig (Fig.  4).  Cells primed in the presence of IL-4 produced 
substantial amounts of IL-4 upon challenge. However, cells 
primed in the presence of both IL-4 and either anti-IL-2 or 
CTLA-4-Ig had little or no capacity to produce IL-4 upon 
restimulation, demonstrating that inhibiting the CD28 path- 
way directly diminishes the ability of cells to be primed for 
IL-4 production. Moreover, the addition of IL-2 to a priming 
culture containing IL-4 and CTLA-4-Ig overcame the inhi- 
bition mediated by CTLA-4-Ig. This reemphasizes the con- 
clusion that CD28 costimulation is required for priming for 
IL-4 production only through its capacity to regulate IL-2 
production. 
Priming for IFN-  y  Requires IL-2 and Can Be Achieved in the 
Presence of CTLA4-Ig  if lL-2 Is Present.  The role of IL-2 
and CD28 in the development of IFN-3,-producing cells was 
examined by culturing naive T cells with APC, peptide, and 
anti-IL-4  (11Bll)  in  the  presence or  absence  of IL-2 and 
CTLA4-Ig (Fig.  5).  Cells cultured with  11Bll  alone were 
able to produce >1,000 U/ml of IFN-y upon restimulation. 
IFN-7 production was markedly diminished in the presence 
of CTLA4-Ig. The addition of exogenous IL-2 to the priming 
cultures increased IFN-'y production three to four-fold. This 
enhancing effect of IL-2 was not diminished by CTLA4-Ig, 
demonstrating that blocking the CD28 pathway in the pres- 
ence of exogenous IL-2 does not prevent priming for IFN-y 
production. Whether IL-2 is absolutely required for naive 
T cells to develop into IFN-'y producers is not directly evalu- 
arable here, since in the presence of anti-IL-2 and the absence 
of IL-4 (a condition necessary for priming for IFN-'y produc- 
tion),  there is no cell yield. 
Discussion 
Previous work (1-9) has demonstrated that lymphokines 
themselves are important regulators of differentiation of naive 
T cells into cells capable of producing IL-4 and IFN-'y. These 
experiments were carried out by culturing naive T  cells for 
short periods with polyclonal mitogens or antigen and ac- 
cessory  cells  in  the  presence  of various  combinations  of 
cytokines. In such studies, IL-2 was present either as a result 
of endogenous production or of addition. We had previously 
shown in an accessory cell-independent system that T  cells 
activated by immobilized anti-CD3 in the presence of IL-4 
but in the absence of IL-2 failed  to secrete IL-4 upon res- 
timulation (3). Recent work (11, 12) has shown that ligand- 
receptor interactions such as those mediated through the CD28 
costimulatory pathway substantially influence cytokine produc- 
tion by T  cells.  This particular pathway is notable for its 















Figure 4.  IL-4  production  is inhibited  in the absence  of IL-2 and sub- 
stantially diminished in the presence  of CTLA4-1g. CD4 + transgenic  T 
cells (4  x  104) were stimulated for 4 d with T-depleted  spleen cells (4 
x  104), peptide (1/xm), nothing, or IL-4 (1,000 U/ml) in the presence 
or absence of  anti-IL-2 (10/~g/ml), CTLA4-Ig  (10 #g/ml), or CTLA4-Ig 
+  II~2 (10 U/ml). Cells were washed, recultured  and II.-4 content was 
assessed as described in Fig. 3. 
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Figure 5.  Priming  for IFN-'y  production  requires  IL-2  and can be achieved 
in the presence  of CTLA4-Ig  if 1I--2 is present. CD4 + transgenic  T cells 
(4 x  104)  were stimulated for 4 d with T-depleted  spleen  (4 x  104), pep- 
tide (1 #m), nothing, or 11Bll (10 #g/ml) alone or in the presence  of 
CTLA4-Ig  (10/xg/ml), anti-IL-2  (10/xg/ml), or IL-2  (10 U/ml) _ CTLA4- 
Ig. Cells were washed and recultured at 10s/200 gl) with T-depleted 
spleen (10  s) and peptide (1 gm) for 36 h. Supernatants were harvested 
and IFN-y content  was measured  as described  in Materials and Methods. 
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we examined the role of IL-2 in priming for IL-4 production 
and also evaluated whether the CD28 costimulatory pathway 
had an essential,  IL-2-independent  role in this process. 
Stimulation of transgenic T cells with APCs lacking ligands 
for CD28 defined by reactivity with the CTLA4-Ig fusion 
protein failed to permit priming for IL-4 production.  This 
defect could be corrected using anti-CD28  Ab or by addi- 
tion  of exogenous  IL-2.  Similarly,  blocking  stimulation 
through CD28 using CTLA4-Ig with splenic APCs or B7- 
expressing fibroblasts also prevented priming for IL-4 or IFN-3, 
production, an inhibitory effect that also could be overcome 
by addition of IL-2 to the cultures. These data indicate that 
the CD28 costimulatory pathway can play a major role in 
the development of T cells secreting the polar cytokines IL-4 
or IFN-3'. At least in this model system, the role of the CD28 
pathway seems limited to ensuring adequate production of 
IL-2,  rather  than  providing  necessary unique  intracellular 
signals for T cell differentiation and IL-4/IFN- 7 production. 
It remains  possible that  a broadly expressed costimulatory 
ligand present  on COS cells  or the T  cells themselves and 
not reactive with  CTLA4-Ig might  also play a significant 
direct  signaling  role during  IL-4 or IFN-3, priming. 
The  complete  neutralization  of IL-2  in  these  antigen- 
stimulated cultures prevented development of IL-4-producing 
cells. Heinzel et al. (30) have reported that treatment of mice 
infected with Leishmania major with anti-IL-2 Ab decreased 
the amount of IL-4 produced and allowed a majority of the 
mice to heal, suggesting a need for IL-2 in the development 
of IL-4 producing  cells  in vivo.  Thus,  independent  of the 
issue of undetected costimulatory signals,  these results sug- 
gest that IL-2 itself plays a substantial role in the physiologic 
development of effector cytokine responses,  especially of IL-4. 
However, because these experiments are done under controlled 
conditions in vitro and substantial redundancy exists in the 
effects of various cytokines, we cannot exclude the possibility 
that other cytokines may replace IL-2 in the priming process 
under certain conditions.  Studies are underway to examine 
this possibility by utilizing T  cells from mice in which the 
IL-2 gene has been deleted and evaluating whether IL-4 or 
IFN-  3, production is normal after priming and restimulation. 
In addition,  experiments are underway to evaluate whether 
T  cell growth factors such as IL-7 can be used to maintain 
cell viability so that cells primed in the absence of IL-4 and 
IL-2 can be assessed for IFN-y production upon restimulation. 
The absence of a requisite intracellular  signal from the CD28 
pathway in priming for effector cytokine production implies 
that in the presence of IL-2, APCs that lack CD28/CTLA4 
ligands may nonetheless act to prime naive T cells to become 
IL-4 or IFN-3~ producers. In situations in which high levels 
of IL-2 are present, either as a result of endogenous produc- 
tion or pharmacologic intervention, such priming might lead 
to increased immunologically mediated tissue damage or graft 
rejection. Alternatively, it might enhance the protective value 
of an immune response to viral or tumor antigens. The findings 
presented here thus may have relevance to the use of IL-2 
in the clinic,  and to the possible benefit of IL-2 inhibition 
in treatment for conditions in which effector cytokine produc- 
tion results in pathology rather  than  protection. 
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